MapKure, a JV formed by Beijing's BeiGene and SpringWorks Therapeutics of Connecticut, has dosed the first patient in an Australian trial of BeiGene's second-gen B-RAF inhibitor. BGB-3245 is aimed at patients with advanced or refractory solid tumors that have B-RAF mutations. SpringWorks was formed in 2017 as a spin-out from Pfizer with two Pfizer targeted small-molecule oncology drugs. MapKure is also starting a Phase I trial in the US of BGB-3245, which will be an expansion of the Australian trial. More details....
Stock Symbols: (NSDQ: BGNE; HKEX: 06160) (NYSE: PFE)
Share this with colleagues: